Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II
NCT02707055 · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · PHASE2 · terminated · last registry update 2022-03-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Early termination of the study due to the COVID-19 pandemic” | – | Registry record, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GHSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-03Results posted on the registry: M.D. Anderson Cancer Center, Anamorelin Hydrochloride (NCT03035409)
- 2021-12-22Results posted on the registry: Allergan, Placebo + Relamorelin (NCT03420781)
- 2021-12-22Also stopped (terminated): Allergan, Placebo + Relamorelin (NCT03420781)
- 2021-12-15Results posted on the registry: Allergan, Relamorelin 10 μg (NCT03786380)
- 2021-12-15Also stopped (terminated): Allergan, Relamorelin 10 μg (NCT03786380)
- 2021-11-23Results posted on the registry: Allergan, Placebo + Relamorelin (NCT03383146)
- 2021-11-23Also stopped (terminated): Allergan, Placebo + Relamorelin (NCT03383146)
- 2021-08-06Results posted on the registry: Allergan, Placebo + Relamorelin (NCT03426345)
- 2021-08-06Also stopped (terminated): Allergan, Placebo + Relamorelin (NCT03426345)
- 2021-07-29Results posted on the registry: Allergan, Placebo + Relamorelin (NCT03285308)
- 2021-07-29Also stopped (terminated): Allergan, Placebo + Relamorelin (NCT03285308)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision